China Universal Asset Management Co., Ltd. Corvus Pharmaceuticals, Inc. Transaction History
China Universal Asset Management Co., Ltd.
- $1.03 Billion
- Q4 2024
A detailed history of China Universal Asset Management Co., Ltd. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,625 shares of CRVS stock, worth $73,030. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,625Holding current value
$73,030% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding CRVS
# of Institutions
77Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$37.2 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$29.8 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$24.3 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$17.6 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$13 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $250M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...